Business

Danish inhaled drug developer Serendex has announced that it has met a number of milestones this year in preparation for clinical development of its portfolio. According to Serendex, in the first quarter of 2015, the… Read more . . .

Inhaled drug developer Prosonix will be acquired by Circassia Pharmaceuticals for a total of £100 million in cash, the company said. Of that total, £70 million will be paid up front, with an additional £30… Read more . . .

Pharmaxis has announced that beginning in June 2015, Chiesi Farmaceutici will take over the commercialization of the Bronchitol mannitol DPI for the treatment of cystic fibrosis in the UK, Ireland, and Germany. Additionally, Pharmaxis said… Read more . . .

Actavis has announced that it is relaunching 0.25 and 0.5 mg vials of budesonide inhalation suspension, a generic version of AstraZeneca’s Pulmicort Respules, after the United States Court of Appeals for the Federal Circuit lifted… Read more . . .

Pennsylvania-based Egalet Corporation has announced that it will begin promoting Sprix ketorolac tromethamine nasal spray in the second quarter of 2015. Sprix is a non-steroidal anti-inflammatory drug (NSAID) for the short-term treatment of moderate to… Read more . . .

California-based InCarda Therapeutics (formerly Pleiades Cardio-Therapeutics) has announced that it raised over $5 million with the possibility of an additional $1.5 million in a private financing round led by Morningside Venture. According to the company,… Read more . . .

According to Mylan, the United States Court of Appeals for the Federal Circuit has affirmed a lower court’s March 2014 decision upholding the validity of four Mylan patents related to Perforomist formoterol fumarate inhalation solution… Read more . . .

AstraZeneca announced that it has entered into a five-year partnership agreement with patient network PatientsLikeMe for access to patient-reported data in several treatment areas, including respiratory. PatientsLikeMe offers a program called “data for good,” whose… Read more . . .

CDMO Molecular Profiles has announced that the company has a new name: Juniper Pharma Services. The company, whose services include formulation development and clinical trial manufacturing of dry powder inhalers, was acquired in 2013 by… Read more . . .

Vectura has announced that it will close the former Activaero nebulizer manufacturing site in Gemünden, Germany by March 2016, transfering many of the site’s operations to other Vectura facilities in Germany and the UK. Commercial… Read more . . .